Characteristics of epstein barr virus variants associated with gastric carcinoma in Southern Tunisia
Virology Journalvolume 8, Article number: 500 (2011)
EBV-associated Gastric Carcinoma (EBVaGC) has a distinct clinical features and its prevalence is variable worldwide.
To determine the prevalence of EBVaGC in Tunisia, EBV-encoded small RNA (EBER) expression was assessed in 81 gastric carcinoma (GC) specimens. The nuclear EBER expression was detected in 12 out of 81 GC cases (14.81%) and concordance between the score range of EBER staining and the number of EBV DNA copies as estimate by QPCR is observed. On the other hand, we found that EBVaGC strongly correlated with age at diagnosis, and weakly with tumor differentiation and venous invasion.
Furthermore, the EBVaGC specimens were subjected to determine the EBV DNA polymorphisms. Our results show a unique genetic profile of the EBV strains regarding the A and D types, the F prototype, the retention of Xho I restriction site and the 30 bp del-LMP1 variant. According to our previous studies on nasopharyngeal carcinoma (NPC), we suggested that EBV strains associated to GC and NPC shared some similarities in Tunisian patients .
The prevalence of EBVaGC is of 14.81% in the southern Tunisia and that common EBV strain are associated with both NPC and GC which are likely to differ from Asian strains. Our findings support therefore a certain geographical distribution of EBV strains which is not restricted to EBV-associated malignancies.
Gastric carcinoma (GC) is the second leading cause of cancer death worldwide . The incidence of GC varies from one geographic region to another, suggesting that genetic and environmental factors including Helicobacter pylori infection are considered to contribute to gastric carcinogenesis [2, 3]. In southern Tunisia, the annual incidence of GC varies from 2.6 to 4.8/100 000 persons . In the few past years, many reports have explored the association between Epstein-Barr Virus (EBV) infection and GC [5–9]. The EBV-associated GC (EBVaGC) has been evidenced by the presence of uniform expression of EBV-encoded small RNA (EBER) in GC cells , the detection of monoclonal EBV episomes in GC cells  and the increase of serum antibodies against viral capsid antigen . The incidence of EBVaGC varies widely from 2 to 18% as reported by previous studies [13–20]. Moreover, the clinical features of EBVaGC include male predominance, relatively younger age and location in the proximal stomach [9, 21]. The EBVaGC shows a lower rate of lymph-node involvement and has a relatively favourable prognosis compared to EBV-negative one .
In EBVaGC, infection of tumor cells is characterized by a type I pattern of latency, in which the expression of viral latent genes is restricted to Epstein-Barr nuclear antigen (EBNA)-1, EBER, latent membrane protein LMP-2A and transcripts from the Bam HI A rightward frame (BARF)-0 and -1 [11, 23]. Since the EBV products of type I latent infection have been demonstrated to be involved in EBV-mediated tumorogenesis, it was suggested that the oncogenic process in EBVaGC could be driven by different mechanisms from those of conventional GC. Subsequently, EBVaGC malignancy could be considered as a different entity among GC which requires greater attention to improve patient care.
The present study was conducted with the aim to determine the prevalence of EBVaGC in southern Tunisia and subsequently to analyze specific EBV polymorphisms in the tumor isolates.
Materials and methods
A total of 81 primary gastric carcinomas were collected, between January 1999 and December 2009 from patients who underwent radical surgical resection at the Department of Digestive Surgery of Habib Bourguiba University Hospital (Sfax, Tunisia). All patients gave informed consent prior to specimen collection according to institutional guidelines. None of the patients had pre-operative or post-operative chemotherapy. Clinico-pathological parameters such as gender, age, anatomical site, histological type, pathological stage, tumor size and venous invasion were evaluated by reviewing medical charts and pathological records. At the time of surgery, the age of patients ranged from 18 to 94 years (mean: 59.58 years). The anatomical site of tumor was determined according to the predominant location of the lesion as cardia (n = 8), body (n = 22), and antrum (n = 48). The histological subtypes were classified according to the criteria of Lauren  as intestinal type (n = 47) and diffuse type (n = 34) but also of World Health Organization as poorly differentiated (n = 43), moderately differentiated (n = 26) and well-differentiated (n = 9). The clinical stage of the disease was determined according to the tumor, node and metastasis (TNM) classification of the American Joint Committee on Cancer . Our cohort contains 9 patients at stage I or II and 47 patients at stage III or IV.
EBV was identified by the expression of EBV-encoded small RNA (EBER). Briefly, in situ hybridization (ISH) assay was performed on 3 μm paraffin-block sections with EBV oligonucleotide probes complementary to the EBER-1 and -2 according to the manufacturer's instructions (PNA ISH detection kit, Dako Cytomation). The hybridization signals were visualized with diaminobenzidine (DAB) and positive nuclear signal was recognized as dark brown nuclear staining under light microscopy. As positive control, section from a known EBER-positive NPC tissue was used. Staining was scored from 1 to 3 according to the percentage of stained cell nuclei in tissue sections. Score 3 was attributed when positive signal was observed in more than 75%, score 2 in 75 to 50% and score 1 in less than 50% of cells.
DNA was extracted from formalin-fixed, paraffin embedded tissues. After tumor identification on hematoxylin-eosin-stained slides, tumoral areas were scraped from 40 μm thick paraffin sections. The collected materials were de-waxed by washing in xylene and rinsed in ethanol. Dried tissues were digested with proteinase K in presence of SDS at 55°C overnight, followed by phenol/chloroform extraction as described previously . The quantity of DNA was checked by spectrophotometer and stored at -20°C for further use.
PCR- RFLP and Sequencing
Five regions of the EBV genome were targeted for polymorphism analysis by PCR, RFLP or sequencing. The polymorphisms studied encompass the A or B type in the EBNA-3C gene, the C or D type in the BamHI-W1/I1 region, the prototype F or f variant in the BamHI-F region, the loss of an Xho I site in the first exon of BNLF1gene (Xho I-loss variant) and the 30 bp deletion in the third exon of the same gene (30 bp del-LMP1 variant). Genotyping was performed on DNA from GC patients EBV-positive and as control, we analyze 10 DNA samples from nasopharyngeal mucosa positive for EBV .
PCR amplification was performed on 200 ng DNA in a final reaction mixture of 50 μl containing 0.2 μM of each primer, 200 μM of dNTP, 2 mM MgCl2, 1X PCR buffer and 1 unit of Taq DNA polymerase (Fermentas). The primer sequences and the size of PCR products are shown in Table 1.
The C/D and F/f typing is based on the BamHI digestion of each PCR product. The enzymatic reactions were carried out in a final volume of 20 μl containing 10 μl of PCR product, 1X digestion buffer and 10 units of BamHI enzyme (Fermentas). After overnight incubation at 37°C, products were analyzed on 2% agarose gel and visualized by ethidium bromide staining, under UV illumination. The same conditions described above were assessed to identify the XhoI site in the first exon of BNLF1gene. DNA from B95.8 (GenBank accession No.V01555) and C666-1 cell line (GenBank accession No. ABV54173) were used as control for EBV types and variants. The C666-1 cell line derived from a Chinese NPC that harbours A/C types, f variant, Xho I-loss variant and 30 bp del-LMP1 variant.
DNA sequencing was performed on the purified PCR products of the third exon of BNLF1 gene using the SV gel Purification kit (Promega). Cycle sequencing was performed using the ABI PRISM Big Dye Terminator Cycle Sequencing Kit (Applied Biosystems) according to the manufacturer's instructions. All sequences were performed bi-directionally. The sequencing results were then compared with the EBV sequences of B95.8 (GenBank accession No.V01555), Chinese NPCs (Cao cells , C666-1 cells (GenBank accession No. ABV54173) and NPC10 biopsy  and Tunisian NPC specimens (CV4, CV5, and CV6 ).
Real time quantitative PCR
Q-PCR assay targeting the BamHI-W region of the EBV genome was performed on the 12 EBV-positive specimens displaying nuclear staining and 6 EBV negative specimens. Reactions were carried out on an iCycler iQ™ Real-time PCR system (BioRad), using primers flanking the BamHI-W region of the EBV genome and TaqMan probe as described previously . Aliquot of 1 μg DNA was used for amplification in a total reaction volume of 25 μl containing 300 nM of each primer, 25 nM of TaqMan probe, 1X PCR buffer, 2mM MgCl2, 200 μM of each dNTP and 1 unit of GoTaq Hot Start polymerase (Promega). The standard curve was prepared using serial 10-fold dilutions of the recombinant plasmid pGEMT/BamHI-W. Samples were run in duplicate and the results averaged to calculate EBV viral load expressed in copies per reaction.
Statistical analysis was performed with SPSS 13.0 statistical software program for Windows (SPSS Inc., Chicago, Illinois, USA). P-value of less than 0.05 was considered as statistically significant.
Prevalence of EBVaGC and association with clinico-pathological characteristics
Eighty one specimens of GC were tested for EBV positivity using the EBER in situ hybridization. The frequency of EBVaGC was 14.8% (12 of 81) in which the EBER positive signal was restricted to the nuclei of carcinoma cells (Figure 1). The EBVaGC specimens have a variable percentage of stained tumor cells showing more than 75% in six cases (score 3), between 50 and 75% in three cases and less than 50% in the three remaining cases. The EBVaGC cases were associated with age at diagnosis (P = 0.009, Table 2). Indeed, 9 out of the 12 patients with EBVaGC were aged between 45 to 60 years old. In addition, a trend toward association was observed with tumor differentiation and venous invasion as the statically significant value was not reached (P = 0.07 and P = 0.09 respectively, Table 2).
Quantitative assessment of EBV in GC
Q-PCR assay was performed on 18 gastric carcinoma specimens; among them 12 displayed EBER positivity restricted to cells nuclei and 6 were negative.
The viral DNA copy number was estimated by the absolute quantification method using serial dilution of recombinant plasmid DNA (pGEMT/BamHI-W), as external standard. Standard curve was established by plotting the starting plasmid copy number against the threshold cycle (Ct), showing a linear quantification over a range from 106 to 10 copies per reaction.
Representative examples are shown on Figure 2 where cases GC10 and GC3 (Ct = 15 and 22 respectively) display strong EBER nuclear staining whereas GC8 (Ct = 30) exhibits a weak EBER expression (Figure 2). The Q-PCR data is in concordance with EBER in situ hybridization result. Indeed, the 6 specimens with intense EBER staining (score 3+), showed high EBV DNA copy number whereas cases with weak EBER expression (score 1+) corresponded to low viral DNA copy (Table 3).
Genotyping of EBVaGC strains
To further investigate the EBVaGC in our 12 Tunisian specimens, we have examined the genetic profile of EBV strains determining different types and variants. A unique profile in all studied specimens is observed (Figure 3). It was characterized by the A/D types, prototype F, retention of Xho I restriction site and 30 bp del-LMP1 variant. We note that the A and B types shaping two different EBV strains were found in one case of EBVaGC specimens (Figure 3).
The EBV DNA analysis was also performed by partial sequencing on the third exon of the BNLF1 gene encoding amino acids 328 to 376 of the LMP1 protein. In order to confirm the 30 bp deletion encoding amino acids 343 to 352 of the LMP1 protein, sequence alignment revealed seven amino-acids changes compared to the reference strain B95.8. It was constantly found at codons Q334R, L338S and S366A in all EBVaGC specimens. The remaining amino acids substitutions, however, were especially found in one or two EBVaGC specimens: H358L and L359V (GC2), P360H (GC9-10) and G365R (GC6). Regarding our previous data on Tunisian NPC specimens, we found similar results about the three constant amino-acids substitutions. In addition, the EBV strains harbouring S366A substitution appear more associated to Tunisian specimens when compared to those defined in China (Figure 4).
In healthy EBV carriers, polymorphism analysis showed also the A and D types, prototype F and XhoI+ variant, as similar to identify in EBVaGC specimens (data not shown) .
In the present study, 81 cases of GC from patients of the south region of Tunisia were investigated for the presence of EBV and the prevalence of EBVaGC was 14.8% (12 out of 81). It was well known that the prevalence of EBVaGC varies widely from one geographical region to another and the highest frequency was noted in Germany (18%) whereas the lowest one (3.9%) was detected in Peru [13–20, 31].
The EBER in situ hybridization was the most reliable method reported in the literature to detect latent EBV in GC. In fact, all the above mentioned studies were conducted following this method, including our study. The variable proportions of nuclear tumor cells that express EBER showing in our study were also deduced by Truong et al., who suggest to be related with EBV infection occurs in oncogenic process of EBVaGC. However, further investigations must be conducted to clarify this observation .
In addition, we showed that the heterogeneous data of EBER expression could be correlated with the number of EBV DNA copies as estimated by Q-PCR supporting that this method is reliable as reported previously .
With regards to the clinico-pathological features of EBVaGC, strong association with age at diagnosis was observed (P = 0.009, Table 3). In fact, the EBVaGC was more frequently found in the group of patients aged between 45 and 60 years old, which is in line with previous studies [19, 34]. No other statistical association was found, except a tendency with tumor differentiation and venous invasion (P = 0.075 and P = 0.09 respectively). Previous reports have indicated that EBVaGC were frequent in male, proximal stomach and tumors of diffuse type[9, 14, 16, 35–39]. Recently, in a large meta-analyse, Carmago et al., confirms these associations in addition to the age at diagnosis. In our study, we didn't find difference in the distribution of EBV in male compared to female patients, in proximal vs distal stomach and in diffuse vs intestinal histotype. These variations between data could be explained by the contribution of local risk factors in the pathogenesis of EBV and also by the size and charasteristics of the cohort .
Polymorphism analysis of the 12 EBVaGC cases show exclusively the type D, prototype F, Xho I-retention and the 30 bp del-LMP1 variant. Concerning the polymorphism of the EBNA-3C gene, we found the A type in all EBVaGC cases and a combination of types A and B was found in only one case. These findings are in agreement with recent study conducted on four EBVaGC cases from the central region of Tunisia .
The predominance of type A and prototype F was also shown in previous reports independently to the geographic origin of EBVaGC as in southern China , southern Japan , and Latin American countries . Interestingly, the variant-f was especially described in NPC associated EBV strains of southern Asia . In this area, a predominance of C type and loss-XhoI variant was observed in patients with EBVaGC or NPC [35, 40], in contrast to our present finding and previous data on Tunisian NPC patients [29, 43].
To better define the genotype of EBVaGC strains and compare them with those associated with the NPC, we carried out the partial sequencing of exon 3 of the BNLF1 gene and compared them to the prototype B95-8 and others published sequences from Asian and Tunisian NPC EBV strains [29, 43]. The Q334R, L338S and L338P were found in all our EBV isolates and were already reported in EBV strains associated to NPC originating from China or Tunisia [29, 44]. However, the S366A is specific to EBV isolates associated with Tunisian NPC and GC.. Indeed, and based on the previous report of Edwards et al. ,describing seven phylogenetically distinct strains of LMP1, we can propose that Tunisian isolates constitute a supplementary group with a specific signature (T366A) but this hypothesis needs confirmation by sequencing of the entire BNLF1 gene in these isolates. According to this date, we suggest that polymorphism in the BNLF1 gene constitute an additional argument in line with the others EBV polymorphisms (D type, prototype F and XhoI+) supporting the dissimilarity of EBV strains between the two geographic regions .
On the other hand, we have described previously others del-LMP1 variants (69 bp and 81 bp deletion spanning codons 334-353 and 345-371, respectively) in Tunisian NPC patients [29, 43]. These variants were not found and only the 30 bp del-LMP1 variant was identified in all EBVaGC cases as already reported by Chen et al., in a large study conducted on Chinese GC patients .
Our polymorphism analysis of EBV isolates in healthy carriers revealed an identical genotype to those of EBVaGC and NPC suggesting that common strains are geographically distributed but not associated with a specific malignancy. In fact, the development of EBV associated malignancies could be correlated to variation in potential immune recognition in distinct populations and individuals, as proposed by Edwards et al ,.
The prevalence of EBVaGC in patients from southern Tunisia is 14.8% which is in range with reported data. The EBVaGC was predominantly found in the group of patients aged from 45 to 60 years old and that EBV DNA level reflect the EBER status in gastric carcinoma.
Furthermore, EBV strains associated to Tunisian patients with GC or NPC share some similarities suggesting that probably the same EBV strain are associated with both tumors. Altogether, our findings support the different geographical distribution of EBV strains, but not their restriction to an associated malignancy.
Correa P, Piazuelo MB, Camargo MC: The future of gastric cancer prevention. Gastric Cancer 2004, 7: 9-16. 10.1007/s10120-003-0265-0
Rocco A, Staibano S, Ottini L, Mezza E, Somma P, Mariani-Costantini R: Is there a link between environmental factors and genetic predisposition to cancer? A lesson from a familial cluster of gastric cancer. Eur J Cancer 2003, 39: 1619-1624. 10.1016/S0959-8049(03)00368-X
Yustein AS, Harper JC, Petroni GR, Cummings OW, Moskaluk CA, Powell SM: Allelotype of gastric adenocarcinoma. Cancer Resv 1999, 59: 1437-1441.
Hsairi M, Fakfakh R, Ben Abdallah M, Jelidi R, Sellami A, Nacef T: Assessment of cancer incidence in Tunisia. La Tunisie Médicale 2002, 80: 57-64.
Fukayama M, shiku T: Epstein Barr virus associated gastric carcinoma. Pathol Res and Pract 2011, 207: 529-537. 10.1016/j.prp.2011.07.004
Lee JH, Kim SH, Han SH, An JS, Lee ES, Kim YS: Clinicopathological and molecular characteristics of Epstein-Barr virus-associated gastric carcinoma: a meta-analysis. J Gastroenterol Hepatol 2009, 24: 354-365. 10.1111/j.1440-1746.2009.05775.x
Osato T, Imai S: Epstein-Barr virus and gastric carcinoma. Semin Cancer Biol 1996, 7: 175-182. 10.1006/scbi.1996.0024
Tokunaga M, Land CE, Uemura Y, Tokudome T, Tanaka S, Sato E: Epstein-Barr virus in gastric carcinoma. Am J Pathol 1993, 143: 1250-1254.
Uozaki H, Fukayama M: Epstein-Barr virus associated gastric carcinoma-viral carcinogenesis through epigenetic mechanisms. Int J Clin Exp Pathol 2008, 1: 198-216.
Takada K, Nanbo A: The role of EBERs in oncogenesis. Semin Cancer Biol 2001, 11: 461-467. 10.1006/scbi.2001.0413
Imai S, Koizumi S, Sugiura M, Tokunaga M, Uemura Y, Yamamoto N, Tanaka S, Sato E, Osato T: Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc Natl Acad Sci USA 1994, 91: 9131-9135. 10.1073/pnas.91.19.9131
Shinkura R, Yamamoto N, Koriyama C, Shinmura Y, Eizuru Y, Tokunaga M: Epstein-Barr virus-specific antibodies in Epstein-Barr virus-positive and -negative gastric carcinoma cases in Japan. J Med Virol 2000, 60: 411-416. 10.1002/(SICI)1096-9071(200004)60:4<411::AID-JMV8>3.0.CO;2-8
Abdirad A, Ghaderi-Sohi S, Shuyama K, Koriyama C, Nadimi-Barforoosh H, Emami S, Mosavi-Jarrahi A, Nahvijou A, Akiba S: Epstein-Barr virus associated gastric carcinoma: a report from Iran in the last four decades. Diagn Pathol 2007, 15: 22-25.
Alipov G, Nakayama T, Nakashima M, Wen CY, Niino D, Kondo H, Pruglo Y, Sekine I: Epstein-Barr virus-associated gastric carcinoma in Kazakhstan. World J Gastroenterol 2005, 11: 27-30.
Burgess DE, Woodman CB, Flavell KJ, Rowlands DC, Crocker J, Scott K, Biddulph JP, Young LS, Murray PG: Low prevalence of Epstein-Barr virus in incident gastric adenocarcinomas from the United Kingdom. Br J Cancer 2002, 86: 702-704. 10.1038/sj.bjc.6600107
Chang MS, Lee HS, Kim CW, Kim YI, Kim WH: Clinicopathologic characteristics of Epstein-Barr virus-incorporated gastric cancers in Korea. Pathol Res Pract 2001, 197: 395-400. 10.1078/0344-0338-00052
Corvalan A, Koriyama C, Akiba S, Backhouse C, Palma M, Argandoña J, Tokunaga M: Epstein-Barr virus in gastric carcinoma is associated with location in the cardia and with a diffuse histology: a study in one area of Chile. Int J Cancer 2001, 94: 527-530. 10.1002/ijc.1510
Hao Z, Koriyama C, Akiba S, Li J, Luo X, Itoh T, Eizuru Y, Zou J: The Epstein-Barr virus- associated gastric carcinoma in Southern and Northern China. Oncol Rep 2002, 9: 1293-1298.
Herrera-Goepfert R, Akiba S, Koriyama C, Ding S, Reyes E, Itoh T, Minakami Y, Eizuru Y: Epstein-Barr virus-associated gastric carcinoma: evidence of age-dependant among a Mexican population. W J Gastroenterol 2005, 11: 6096-6103.
Karim N, Pallesen G: Epstein-Barr virus (EBV) and gastric carcinoma in Malaysian patients. J Pathol 2003, 25: 45-47.
Murphy G, Pfeiffer R, Camargo MC, Rabkin CS: Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology 2009, 137: 824-833. 10.1053/j.gastro.2009.05.001
Fukayama M, Hino R, Uozaki H: Epstein-Barr virus and gastric carcinoma: virus-host interactions leading to carcinoma. Cancer Sci 2008, 99: 1726-1733. 10.1111/j.1349-7006.2008.00888.x
Zur Hausen A, Brink AA, Craanen ME, Middeldorp JM, Meijer CJ, Van Den Brule AJ: Unique transcription pattern of Epstein-Barr virus (EBV) in EBV-carrying gastric adenocarcinomas: expression of the transforming BARF1 gene. Cancer Res 2000, 60: 2745-2748.
Lauren P: The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965, 64: 31-49.
Sobin LH, Fleming ID: TNM classification of malignant tumors, fifth edition Union. Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997, 80: 1803-1804. 10.1002/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9
Sambrook J, Russell DW: Molecular cloning. A laboratory manual, Cold Spring Harbor, NY; Cold Spring Harbor Laboratory Press; 2001.
Hu LF, Zabarovsky ER, Chen F, Cao SL, Ernberg I, Klein G, Winberg G: Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP1) from Chinese nasopharyngeal carcinoma. J Gen Virol 1991, 72: 2399-2409. 10.1099/0022-1317-72-10-2399
Cheung ST, Leung SF, Lo KW, Chiu KW, Tam SJ, Fok TF, Johnson PJ, Lee JC, Huang DP: Specific latent membrane protein 1 gene sequences in type1 and type 2 Epstein Barr virus from nasopharyngeal carcinoma in Hong Kong. Int J Cancer 1998, 76: 399-406. 10.1002/(SICI)1097-0215(19980504)76:3<399::AID-IJC18>3.0.CO;2-6
Hadhri-Guiga B, Khabir AM, Mokdad-Gargouri R, Ghorbel AM, Drira M, Daoud J, Frikha M, Jlidi R, Gargouri A: Various 30 and 69 bp deletion variants of the Epstein-Barr virus LMP1 may arise by homologous recombination in nasopharyngeal carcinoma of Tunisian patients. Virus Res 2006, 115: 24-30. 10.1016/j.virusres.2005.07.002
Lo YM, Chan LY, Chan AT, Leung SF, Lo KW, Zhang J, Lee JC, Hjelm NM, Johnson PJ, Huang DP: Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res 1991, 59: 5452-5455.
Yoshiwara E, Koriyama C, Akiba S, Itoh T, Minakami Y, Chirinos JL, Watanabe J, Takano J, Miyagui J, Hidalgo H, Chacon P, Linares V, Eizuru Y: Epstein-Barr virus-associated gastric carcinoma in Lima, Peru. Jpn J Cancer Res 2005, 24: 49-54.
Truong CD, Feng W, Li W, Khoury T, Li Q, Alrawi S, Yu Y, Xie K, Yao J, Tan D: Characteristics of Epstein-Barr virus-associated gastric cancer: a study of 235 cases at a comprehensive cancer center in USA. J Exp Clin Cancer Res 2009,3(28):14.
Ryan JL, Morgan DR, Dominguez RL, Thorne LB, Elmore SH, Lauwers GY, Booker JK, Gulley ML: High Levels of Epstein-Barr Virus DNA in Latently Infected Gastric Adenocarcinoma. Lab Invest 2009, 89: 80-90. 10.1038/labinvest.2008.103
Trimeche M, Ksiaa F, Ziadi S, Mestiri S, Hachana M, Ben Gacem R, Sriha B, Korbi S: Prevalence and characteristics of Epstein-Barr virus-associated gastric carcinomas in Tunisia. Eur J Gastro Hepato 2009, 21: 1001-1007. 10.1097/MEG.0b013e32831f1f53
Chen JN, Ding YG, Feng ZY, Li HG, He D, Du H, Wu B, Shao CK: Asociation of distinctive Epstein-Barr virus variants with gastric carcinoma in Guangzhou, southern China. J Med Virol 2010, 82: 658-667. 10.1002/jmv.21731
Galetsky SA, Tsvetnov VV, Land CE, Afanasieva TA, Petrovichev NN, Gurtsevitch VE, Tokunaga M: Epstein-Barr-virus-associated gastric cancer in Russia. Int J Cancer 1997, 73: 786-789. 10.1002/(SICI)1097-0215(19971210)73:6<786::AID-IJC2>3.0.CO;2-Z
Murphy G, Pfeiffer R, Camargo MC, Rabkin CS: Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology 2009, 137: 824-833. 10.1053/j.gastro.2009.05.001
Camargo MC, Murphy G, Koriyama C, Pfeiffer RM, Kim WH, Herrera-Goepfert R, Corvalan AH, Carrascal E, Abdirad A, Anwar M, Hao Z, Kattoor J, Yoshiwara-Wakabayashi E, Eizuru Y, Rabkin CS, Akiba S: Determinants of Epstein-Barr virus-positive gastric cancer: an international pooled analysis. Br J Cancer 2011, 105: 38-43. 10.1038/bjc.2011.215
Fukayama M, Ushiku T: Epstein-Barr virus-associated gastric carcinoma. Pathol Res and Practice 2011, 207: 529-537. 10.1016/j.prp.2011.07.004
Sidagis J, Ueno K, Tokunaga M, Ohyama M, Eizuru Y: Molecular epidemiology of Epstein-Barr virus (EBV) in EBV-related malignancies. Int J Cancer 1997, 72: 72-76. 10.1002/(SICI)1097-0215(19970703)72:1<72::AID-IJC11>3.0.CO;2-C
Corvalan A, Ding S, Koriyama C, Carrascal E, Carrasquilla G, Backhouse C, Urzua L, Argandona J, Palma M, Eizuru Y, Akiba S: Association of a distinctive strain of Epstein-Barr virus with gastric carcinoma. Int J Cancer 2006, 118: 1736-1742. 10.1002/ijc.21530
Lung ML, Lam WP, Sham J, Choy D, Yong-Sheng Z, Guo HY, Ng MH: Detection and prevalence of the ''f'' variant of Epstein-Barr virus in southern China. Virology 1991, 185: 67-71. 10.1016/0042-6822(91)90754-Y
Ayadi W, Feki L, Khabir A, Boudawara T, Ghorbel A, Charfeddine I, Daoud J, Frikha M, Hammami A, Karray-Hakim H: Polymorphism analysis of Epstein-Barr virus isolates of nasopharyngeal carcinoma biopsies from Tunisian patients. Virus Genes 2007, 34: 137-145. 10.1007/s11262-006-0051-2
Edwards RH, Sitki-Green D, Moore D T, Raab-Traub N: Potential Selection of LMP1 Variants in Nasopharyngeal Carcinoma. J Virol 2004, 78: 868-881. 10.1128/JVI.78.2.868-881.2004
This work was supported by a grant of the Tunisian Ministry of high Education and Scientific Research. We wish to thank Mr M Jaoua for sequencing facilities.
The authors declare that they have no competing interests.
DBG carried out the molecular genetic studies, EBER in situ-hybridization and drafted the manuscript. WA carried out the Q-PCR, and drafted the manuscript. IMA contributed to sequence alignment, and drafted the manuscript. AK participates to the EBER in situ- hybridization and carried out the pathological workup. TSB participate to the design of the study. AG participates to the design of the study and drafted the manuscript. RMG carried out the statistical analysis, conceived the study and wrote the paper. All authors read and approved the final manuscript.